Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Long-term Extension Study of PCI-32765 (Ibrutinib)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01804686
Recruitment Status : Enrolling by invitation
First Posted : March 5, 2013
Last Update Posted : October 18, 2019
Sponsor:
Collaborator:
Pharmacyclics LLC.
Information provided by (Responsible Party):
Janssen Research & Development, LLC

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Enrolling by invitation
Estimated Primary Completion Date : December 29, 2021
Estimated Study Completion Date : December 31, 2026